Latest news

• Takeda to acquire Nimbus’ TYK2 inhibitor in deal worth $6bn

  Nimbus recently announced positive top-line results from a phase 2b study evaluating NDI-034858, which will be known as TAK-279 upon completion of the transaction, for patients with ... Earlier this month, Takeda’s dengue vaccine candidate, Qdenga

• Takeda’s dengue vaccine receives EC approval

  Takeda’s dengue vaccine candidate, Qdenga (TAK-003), has been approved by the European Commission (EC) for the prevention of dengue disease in individuals aged four years and over, the company

• Takeda’s dengue vaccine candidate recommended for approval by CHMP

  Takeda’s dengue vaccine candidate, TAK-003, has been recommended for conditional marketing authorisation for the prevention of dengue disease caused by any serotype in individuals four years and older in ... the follow-up, TAK-003 prevented 84% of

• Takeda highlights 12 NMEs with $10bn-plus sales potential at R&D day

  Dengue vaccine TAK-003:Takeda’s dengue fever vaccine candidate  TAK-003 hit the efficacy mark in a large-scale study reported earlier this month, and seems to be safe in ... In September, it presented proof-of-concept data suggesting one candidate –

• Takeda’s dengue vaccine seems safe with no prior virus exposure

  Appears unaffected by serious safety issue affecting Sanofi rival. Takeda says new data shows its candidate vaccine for dengue fever TAK-003 is effective, and crucially doesn’t seem to be ... It’s also investing in production capacity for TAK-003,